DelveInsight’s Trending Reports 2022: Chondrosarcoma Market, Microsatellite Stable Colorectal Cancer Market, Rituximab Biosimilars Insight, Pain Management Devices Market, 22q11.2 Deletion Syndrome Market.

Chondrosarcoma Market

Chondrosarcoma is a bone sarcoma that develops in the cartilage cells. It mostly affects adults above the age of 40 and the most common sites are the upper arm, pelvis and thigh bone. Chondrosarcomas can be subdivided in several ways: by histologic grade, whether they arise de novo (primary) or from benign lesions (secondary), by location within the bone (central or peripheral), or by syndrome.

Some of the facts:

·         According to the US Surveillance, Epidemiology and End Results Program, Chondrosarcomas contribute 30% among different types of bone cancer.

·         Chondrosarcomas develops most often in adults, with an average age at diagnosis of 51. Less than 5% of cases occur in patients younger than 20.

·         Chondrosarcoma is a tumor of adulthood and older age. The majority of patients are older than 50 years of age at diagnosis, with a slight male predominance.

·         Chondrosarcomas are sporadic, but they may develop from the malignant transformation of osteochondromas and enchondromas. Malignant transformation occurs in 5% of osteochondromas, either multiple or solitary forms.

Request for free sample report: https://www.delveinsight.com/report-store/chondrosarcoma-market

Some of the Chondrosarcoma Companies:

·         Agios Pharmaceuticals

·         Forma Therapeutics

·         Eli Lilly and Company

·         PharmaMar

·         And Many Others

Chondrosarcoma Drugs Covered:

·         AG-120

·         Olutasidenib

·         LY3410738

·         Trabectedin

·         And Many Others

Request for free sample report: https://www.delveinsight.com/report-store/chondrosarcoma-market

 

Microsatellite Stable Colorectal Cancer Market

Microsatellite stable colorectal cancer bears fewer signals that alert the immune system to cancer. So checkpoint inhibitors, such as nivolumab, have been unsuccessful in treating MSS colorectal cancer (CRC). Clinical trials have been going on to develop the promising drug for MSS colorectal cancer.

Some facts of Microsatellite Stable Colorectal Cancer Market Report are:

·         Approximately 15% of colorectal cancers (CRC) display MSI owing either to epigenetic silencing of MLH1 or a germline mutation in one of the mismatch repair genes MLH1, MSH2, MSH6 or PMS2.

·         According to DelveInsight, Microsatellite Stable Colorectal Cancer Market is expected to grow at CAGR of XX% during the forecast period.

·         Keytruda, Opdivo with or without Yervoy, and Braftovi in combination with Erbitux are recent additions to the Metastatic Colorectal Cancer treatment market.

·         Talking about gender-predisposition, CRC is the third most commonly diagnosed cancer in males and the second in females. It is most frequently diagnosed in people of age group 65–74.

Request for Free Sample Report: https://www.delveinsight.com/report-store/microsatellite-stable-colorectal-cancer-market

Some of Microsatellite Stable Colorectal Cancer Companies in the market:

  • Gritstone Oncology
  • Merck Sharp & Dohme Corp.
  • Arrys Therapeutics
  • NeoImmuneTech
  • And Others

Request for Free Sample Report: https://www.delveinsight.com/report-store/microsatellite-stable-colorectal-cancer-market

Microsatellite Stable Colorectal Cancer Drugs:

  • GRANITE
  • MK7123-034
  • NT-I7
  • TPST-149
  • And Many Others

Request for Free Sample Report: https://www.delveinsight.com/report-store/microsatellite-stable-colorectal-cancer-market

 

Rituximab Biosimilars Insight

Rituximab is a type of antibody therapy, which can be used alone or with chemotherapy. They work in different ways to catch and attack the cells where cancer occurs. Rituximab targets and attaches to the CD20 protein found on the surface of blood cells with cancer and some healthy blood cells. Rituximab is used for treating certain types of cancer. It works by reducing or prohibiting the growth of cancer cells. This drug is also used for treatment of certain types of blood vessel disease, decrease the swelling of the blood vessels, and treat a specific skin condition.

Have a query? Ask our Experts @ https://www.delveinsight.com/report-store/rituximab-biosimilars-insight

Rituximab Biosimilars Drugs covered in the report:-

  • IBI-301
  • RGB 03
  • RITUMAX
  •  ABP 798
  •  AcellBia/Usmal
  • Blitzima/Truxima
  • BX 2336
  •  DRL_RI
  •  GP2013
  • HLX01
  • iBio Rituximab
  • IBPB 001RX
  • MK-8808
  •  Ritemvia/Blitzima
  • Riximyo
  • RTXM83
  • Ruxience
  •  AP 052
  •  Retuxira
  •  TL-011
  •  RituxiRel
  •  Kikuzubam
  •  LBRx
  •  DRL-rituximab
  • MG1106
  •  GB-241
  •  Rilast
  •  HS 006
  • BX 2336
  • GNR-006

Have a query? Ask our Experts @ https://www.delveinsight.com/report-store/rituximab-biosimilars-insight

Scope of Rituximab Biosimilars report:

  • Major Players in Rituximab –  35+ key companies
  • Phases – 35+ products under different phases of clinical development
    •  Marketed stage products
    •  Late-stage products (BLA Filed and Phase III)
    •  Mid-stage products (Phase II)
    •  Early-stage products (Phase I)
    •  Pre-clinical and Discovery stage candidates
    •  Discontinued & Inactive candidates
    •  Route of Administration
  •  Route of Administration     
    • Subcutaneous
    • Intravenous
    • Molecule Type
  • Molecule types

    • Monoclonal antibodies
    • Peptide
    • Protein
    • Small molecule
    • Product Type

Product Types

  • Mono
  • Combination
  • Mono/Combination

Have a query? Ask our Experts @ https://www.delveinsight.com/report-store/rituximab-biosimilars-insight

 

Pain Management Devices Market

Pain management is a field of medical science that makes it easier for people with chronic pain who suffer. Acute pain has a rapid onset of action, while chronic pain lasts for a prolonged period of time, causing it to to be managed. Pain management device is a medical system used to treat various forms of pain, such as neuropathic pain, cancer pain, nociceptive pain, musculoskeletal pain, and others.

Some key facts of the Pain Management Devices Market:

·         Global Pain Management Devices Market is expected to grow at a CAGR of 7.89% during the forecast period from 2021 to 2026.

·         The demand for Pain Management Devices is primarily motivated by the rise in prevalence of chronic pain, high prevalence of musculoskeletal disorders, surge in geriatric population, surge in awareness among people toward pain management devices, improved R&D investment to develop innovative products, and increasing cost of healthcare expenditure.

·         According to World Health Organization (2019), the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018.

View Report: https://www.delveinsight.com/report-store/pain-management-devices-market

Some of the Pain Management Devices Companies are:

·         St. Jude Medical, Inc.

·         Boston Scientific Corporation

·         Medtronic plc

·         Smiths Medical

·         Abbott

·         Nevro Corp.

·         Stimwave LLC

·         And Many More

Pain Management Devices Market Drivers

·         Growing need for long-term pain relief in the geriatric consumer

·         Large & rising population base of patients

·         Adverse effects of pain medications

·         Widely demonstrated effectiveness of pain management devices

View Report: https://www.delveinsight.com/report-store/pain-management-devices-market

 

22q11.2 Deletion Syndrome Market

22q11.2 Deletion Syndrome is a condition that develops because of chromosome defects and is a complex, multi-organ disorder noted for its varying severity and penetrance among those affected. As per several studies, it is the most common chromosomal microdeletion reported in humans.

Some facts of 22q11.2 Deletion Syndrome Market are:

  • In 2020, the total prevalent cases of 22q11.2 deletion syndrome were 196,476 in the 7MM. The United States, in the same year, accounted for 83,326 cases, the highest prevalence of 22q11.2 deletion syndrome cases in the 7MM, accounting for approximately 42% of the total 7MM cases in 2020.
  • Among the EU-5 countries, the highest number of cases of 22q11.2 deletion syndrome were in Germany and the least in Spain in 2020.
  • 22q11.2 deletion syndrome is often underdiagnosed and misdiagnosed, as the symptoms vary from patient to patient. In the EU-5 countries, the total diagnosed prevalent cases of 22q11.2 deletion syndrome were 35,203 in 2020.

·         22q11.2 deletion syndrome is a multisystem disorder characterized by several physical, behavioral and psychiatric disorders. In the 7MM, of the focused age-group 6 to 12 and 13 to 17 years, the diagnosed prevalent cases of 22q11.2 deletion syndrome with Behavioral and Psychiatric Phenotypes were 36,702, in 2020.

View Report: https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market

Some of 22q11.2 Deletion Syndrome Companies are:

·         Zynerba Pharmaceuticals

·         Enzyvant

·         Roivant Sciences

·         Sumitomo Dainippon Pharma

·         And Many Others

Some of 22q11.2 Deletion Syndrome Therapies are:

·         Zygel (ZYN002)

·         RVT-802

·         And Many Others

View Report: https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market

 

Get in touch with our Business executive for Rich and Deep Healthcare Consulting Solutions

DelveInsight’s Competitive Intelligence Service includes a multidimensional coverage, helping to keep track of competitors and gain traction in the dynamic market by overcoming the challenges and expediting business growth through a strategic and tactical approach.

Some of Newly Launched Report: 

Related Blogs:

About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Email: info@delveinsight.com

Phone: +19193216187

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com

Connect With Us at:

LinkedIn | Facebook | Twitter

 

Comments

Post a Comment

Popular posts from this blog

How Competitive intelligence is transforming the scenario for Biotech firms?

What is Competitive intelligence service? Competitive intelligence ideally means gathering information on rival business in the market, analyse the information and use the information to strategize to yield positive results. Going by the definition, competitive intelligence assembles actionable information from diverse published and unpublished sources, collected efficiently and ethically. So, analysts performing Competitive intelligence for their clienteles present a detailed picture of the marketplace, forthcoming challenges and the ways to face them, even before the can harm the client’s business. What could it mean? Competitive intelligence can often give a wrong idea, as it may misunderstood as a service which can help gain an advantage over the rivals. However, this is not the case. Competitive intelligence is an ethical and legal practise undertaken involving the study of analytical data, analysing the market and optimizing the relevant and realistic strategies t
Read more

Hypothalamic Obesity Market by DelveInsight

  (New York, USA) DelveInsight’s “ Hypothalamic Obesity Market Insights, Epidemiology, and Market Forecast-2032 ” report delivers an in-depth understanding of Hypothalamic Obesity, historical and forecasted epidemiology as well as the Hypothalamic Obesity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Hypothalamic Obesity market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Hypothalamic Obesity market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Hypothalamic Obesity treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Hypothalamic Obesity market. Request for a Free Sample Report @  Hypothalamic Obesity Market Forecast Some facts of the Hypothalamic Obesity Market Report are: Accordi
Read more

Test

  Partial Seizure Market | Parkinson's Disease Levodopa-Induced Dyskinesia Market | Metabolic Acidosis Market | Hepatitis D Market | Gaucher's disease Market | Gastric Neuroendocrine Tumours Market | Familial Chylomicronemia Syndrome Market | Exocrine Pancreatic Insufficiency Market | Crohn's Disease Market | Contact Dermatitis Market | Concussions Market Size | Chronic Bronchitis Market | Chondrosarcoma Market | Palmar Hyperhidrosis Market | Hpv Induced Cancers Market | Alstrom Syndrome Market | Astigmatism Market | Meningioma Market | Central Retinal Vein Occlusion Market | Intracranial Pressure Monitoring Devices Market | Head And Neck Squamous Cell Carcinoma Market | Hyperopia Market | Thyroid Eye Disease Market | Rett Syndrome Market | Cipn Market | Chemotherapy Induced Peripheral Neuropathy Market | Idiopathic Membranous Nephropathy Market | Walking Impairment In Multiple Sclerosis Market  |  Triple Negative Breast Cancer Market  | Sjogren&#
Read more